CoChat
Sign Up
Cited by 416Diabetes Treatment and ManagementDiabetes Management and ResearchPharmacology and Obesity Treatment

The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone

Open access
DeFronzo, Ralph A., Hissa, Miguel N., Garber, Alan J., Luiz Gross, Jorge, Yuyan Duan, Raina, Ravichandran, Shoba, Chen, Roland S., for the Saxagliptin 014 Study Group·2009·Diabetes Care
DOI 10.2337/dc08-1984PMC PMC2732156
Open this paper in CoChat — free account

Abstract

OBJECTIVE: This 24-week trial assessed the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes with inadequate glycemic control with metformin alone. RESEARCH DESIGN AND METHODS: This was a randomized, double-blind, placebo-controlled study of saxagliptin (2.5, 5, or 10 mg once daily) or placebo plus a stable dose of metformin (1,500–2,500 mg) in 743 patients (A1C ≥7.0 and ≤10.0%). Efficacy analyses were performed using an ANCOVA model using last observation carried forward methodology on primary (A1C) and secondary (fasting plasma glucose [FPG] and postprandial glucose [PPG] area under the curve [AUC]) end points. RESULTS: Saxagliptin (2.5, 5, and 10 mg) plus metformin demonstrated statistically significant adjusted mean decreases from baseline to week 24 versus placebo in A1C (−0.59, −0.69, and −0.58 vs. +0.13%; all P < 0.0001), FPG (−14.31, −22.03, and −20.50 vs. +1.24 mg/dl; all P < 0.0001), and PPG AUC (−8,891, −9,586, and −8,137 vs. −3,291 mg · min/dl; all P < 0.0001). More than twice as many patients achieved A1C <7.0% with 2.5, 5, and 10 mg saxagliptin versus placebo (37, 44, and 44 vs. 17%; all P < 0.0001). β-Cell function and postprandial C-peptide, insulin, and glucagon AUCs improved in all saxagliptin treatment groups at week 24. Incidence of hypoglycemic adverse events and weight reductions were similar to those with placebo. CONCLUSIONS: Saxagliptin once daily added to metformin therapy was generally well tolerated and led to statistically significant improvements in glycemic indexes versus placebo added to metformin in patients with type 2 diabetes inadequately controlled with metformin alone.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc08-1984

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Saxagliptin added to metformin led to clinically and statistically significant reductions in HbA1c from baseline versus metformin/placebo in a 24-week randomized, double-blind, placebo-controlled trial.

    “Saxagliptin added to metformin led to clinically and statistically significant reductions in HbA1c from baseline versus metformin/placebo in a 24-week randomized, double-blind, placebo-controlled trial.”

    From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [41]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [22]Bosi E Camisasca RP Collober C Rochotte E Garber AJ Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007; 30: 890– 895 17277036

Cited by

Sorted by citations

Related

Authors
DeFronzo, R. A., Hissa, M. N., Garber, A. J., Luiz Gross, J., Yuyan Duan, R., Ravichandran, S., Chen, R. S., & for the Saxagliptin 014 Study Group
Affiliations
  • The University of Texas at San Antonio Health Science Center (US)
  • Hospital Universitário Walter Cantídio (BR)
  • Baylor College of Medicine (US)
  • Centro De Pesquisa Em Diabetes, Porto Alegre, Rio Grande Do Sul, Brazil;
  • Bristol-Myers Squibb Company, Princeton, New Jersey.
  • Bristol-Myers Squibb (United States) (US)
Corresponding author
DeFronzo, Ralph A.
ORCID
DeFronzo, Ralph A.
Venue
Diabetes Care
Publisher
American Diabetes Association
Published
2009-05-28
Volume
32
Issue
9
Pages
1649-1655
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
DOI
10.2337/dc08-1984
PMC
PMC2732156
OpenAlex
W2103058881
Cited by
416
References
22
Citations by year
2026: 4 · 2025: 3 · 2024: 3 · 2023: 4 · 2022: 7 · 2021: 3 · 2020: 11 · 2019: 8 · 2018: 8 · 2017: 23 · 2016: 31 · 2015: 29 · 2014: 44 · 2013: 34 · 2012: 49
FWCI
49.05
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
Keywords
saxagliptin, metformin, type 2 diabetes, adjunctive therapy, inadequate glycemic control, glycemic control, HbA1c, fasting blood glucose, postprandial blood glucose, beta-cell function, C-peptide, hypoglycemia, drug safety, weight loss, DPP-4 inhibitors, DPP-4 inhibition, insulin secretion, glucagon
MeSH terms
Adamantane, Adolescent, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Dipeptides, Double-Blind Method, Female, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Placebos, Treatment Outcome, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review